Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the safety of ICX-RHY-013 in the treatment of stable, restrictive scars in subjects who have suffered a burn injury. Evaluation will be achieved through regular assessment of adverse events, vital signs, blood work monitoring and laboratory analysis cellular properties of the scar through biopsy.

The secondary objectives of this study are to evaluate improvement in symptoms of scars including reduced pain, discomfort and itching, improvement in mobility and daily function, improvement in appearance and scar texture.


Clinical Trial Description

Restrictive scar contracture (a condition where tissue thickens and tightens, pulling the surrounding healthy skin toward the damaged area) due to a serious burn injury can result in long term aesthetic and physical consequences.

Skin contractures adjacent to a joint lead to joint deformities that severely restrict range of motion (ROM) of the affected joint. Skin contractures are also often accompanied by crippling levels of chronic pain resulting in a high level of dependency on pain medications. These isolated or combined factors can lead to a significant disruption in both social and professional life, leading to a marked impact on an individual's quality of life.

The current standard of care for restrictive scar contracture involves the surgical excision of the contracture itself and/ or skin grafting. These standard therapies require extensive and often repeated surgeries. Physicians are continually seeking less invasive therapies to treat patients with burn contractures.

ICX‐RHY‐013 is an investigational medicinal product comprised of viable allogeneic human dermal fibroblast (HDFs) cells suspended in HypoThermosol®-FRS. HDFs are isolated from neonatal foreskin, cryopreserved, thawed and expanded in culture under good manufacturing practice at Intercytex Ltd., United Kingdom. The drug formulation will be 20 million cells per 1 milliliter of HypoThermosol® and will be administered to subjects via intradermal injections at a maximum dose of 0.25 ml (or 5 million cells) per cm² of tissue.

If determined to be safe and effective, it is believed this therapy could, in the future, be delivered in a series of superficial injections and can be carried out in a doctor's office. This treatment could represent a new less invasive therapy of choice for patients with burn contractures, where current recourse would be to surgery. This advance could have significant positive benefits to the patient in terms of:

- no side-effects of surgery

- treatment given in an outpatient environment without the need for expensive hospitalization

- enhanced quality of life

- lower costs

Cohort 1 will consist of 4 participants who are scheduled to have elective body contouring surgery which will consist of the removal of an abdominal incision scar. The investigational drug will be injected into the existing surgical incision (scar) with the investigational drug, ICX-RHY-013. The purpose of this cohort is to evaluate the initial safety of the investigational drug (ICX-RHY-013) in a series of doses on your surgical scar that will then be surgically removed.

Cohorts 2 through 5 will consist of 4 participants each who have burn scars with restrictive scar contractures. The purpose of these cohorts is to evaluate the ongoing safety of the investigational drug (ICX-RHY-013) in post burn scars with restrictive scar contractures. The investigational drug will be injected directly into these scar contractures. Each cohort is unique in that the dose and frequency of the investigational drug received will be different. We will evaluate the safety of the drug between each cohort by assessing all side effects that the participants may experience. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01564407
Study type Interventional
Source University of Pittsburgh
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date January 2011
Completion date February 2014

See also
  Status Clinical Trial Phase
Completed NCT03664505 - Evaluation of the Product Properties of Individualized 3D-compression Garments to Treat Scars N/A
Recruiting NCT05309720 - Dermal Substitution in Pediatric Burns N/A
Not yet recruiting NCT04995302 - Microneedling Therapy With or Without Amnion Bilayer Sheeting on Scar Tissue N/A
Not yet recruiting NCT04557514 - Comparative Study Between Fat Injection And Platelet Rich Plasma In Post Burn Facial Scar N/A
Recruiting NCT05555602 - Observation of the Comfort and Efficacy of CO2 Laser Combined With Cryo 6 for Burn or Linear Scars. N/A
Recruiting NCT05610878 - Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting Phase 1
Recruiting NCT01619917 - The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars N/A
Recruiting NCT01488240 - The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars N/A
Completed NCT03197649 - CO2 Laser Phototherapy for Management of Mature Burn Scars N/A
Completed NCT04619589 - Characterization of Dyschromic Hypertrophic Scar
Completed NCT03627650 - Fat Grafting in Skin-grafted Deep Burn Scars N/A
Completed NCT02417818 - Cutaneous Microcirculation After Plasma Therapy N/A
Completed NCT02417779 - Cutaneous Microcirculation After Extracorporeal Shock Wave Therapy N/A
Withdrawn NCT01075165 - Efficacy of Spray Silicone in Alteration of Burn Scar N/A
Recruiting NCT04364217 - Pain and Itch Reduction in Burn Scars Treated With Fractional CO2 Laser N/A
Completed NCT04412759 - PORCINE XENOGRAFT OR MICROBIAL CELLULOSE IN THE TREATMENT OF PARTIAL THICKNESS BURNS N/A
Recruiting NCT06122090 - Treatment of Hypopigmented Scars With Bimatoprost Phase 2
Recruiting NCT05423613 - Microneedling for Burn Hypertrophic Scars N/A
Active, not recruiting NCT04456127 - CO2 Laser Revision for Burn Related Donor Site Scars N/A
Completed NCT03544697 - Easy Way of Choosing Rectangular Expander and Getting Maximum Benefit From Expanded Tissue